Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Meera Mohan, MD, Samantha Kendrick, PhD, Yadav Pandey, MD, Richa Parikh, MD, Phil Farmer, Mathew Kottarathara, MD, Shadiqul Hoque, MD, Angel Mitma, MD, Sharmilan Thanendrarajan, MD, Carolina D. Schinke, MD, Guido Tricot, MD PhD, Maurizio Zangari, MD FACP, Frits van Rhee, MD

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139943

Published: 2020

Journal Articles

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Kristin Larsen, Meera Mohan, MD, Clyde Bailey, Kerri Hill, Horace Spencer, Mathew Kottarathara, MD, Richa Parikh, MD, Shadiqul Hoque, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-142527

Published: 2020

Journal Articles

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

David Baker, Milan Bimali, PhD, Luis Carrillo, MD, Archana Sachedina, Daisy Alapat, MD, Md shadiqul Hoque, MD, Mathew Kottarathara, MD, Richa Parikh, MD, Amani Erra, MD, Angel Mitma, MD, Pankaj Mathur, MD, Guido Tricot, MD PhD, Sharmilan Thanendrarajan, MD, Maurizio Zangari, MD FACP, Frits van Rhee, MD, Carolina D. Schinke, MD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-138877

Published: 2020

Journal Articles

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Sandra Susanibar, MD, Pingping Qu, Antje Hoering, Sharmilan Thanendrarajan, MD, Jorge Jo Kamimoto, MD, Meera Mohan, MD, Pankaj Mathur, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Phil Farmer, Nathan Petty, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E. Davies, MD, Daisy Alapat, MD, Barlogie Bart, Gareth J. Morgan, MD PhD, Carolina D. Schinke, MD

Blood (2017) 130 (Supplement 1): 3047.

https://doi.org/10.1182/blood.V130.Suppl_1.3047.3047

Published: 2017

Journal Articles

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Sharmilan Thanendrarajan, MD, Jerry Puryear, PharmD, Carolina D. Schinke, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Pankaj Mathur, MD, Meera Mohan, MD, Sandra Susanibar, MD, Jorge Jo Kamimoto, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Phil Farmer, Leo Rasche, MD, Niels Weinhold, PhD, Brian A Walker, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2017) 130 (Supplement 1): 1858.

https://doi.org/10.1182/blood.V130.Suppl_1.1858.1858

Published: 2017

Journal Articles

Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma

Sandra Susanibar, MD, Victoria Carlton, PhD, Sharmilan Thanendrarajan, MD, Meera Mohan, MD, Pankaj Mathur, MD, Shadiqul Hoque, MD, Muthukumar Radhakrishnan, MD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Faith E Davies, MD, Katherine A. Kong, PhD, Gareth J Morgan, MD PhD, Daisy V. Alapat, MD, Carolina Schinke, MD

Blood (2016) 128 (22): 377.

https://doi.org/10.1182/blood.V128.22.377.377

Published: 2016

Journal Articles

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Blood (2016) 128 (22): 2064.

https://doi.org/10.1182/blood.V128.22.2064.2064

Published: 2016

NARROW

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome

Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission

Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT

Clinical and Molecular Characterization of Primary Plasma Cell Leukemia

Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma

Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma

Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only